{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:03:27Z","timestamp":1742443407919,"version":"3.40.1"},"reference-count":30,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2024,11,18]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Prescribing the optimal combination of anti-tuberculosis drugs at the right dose is a fundamental step to achieve successful treatment outcomes. To aid the decision, clinicians should consider multiple factors, such as body weight, age, results of drug susceptibility testing, risk of intolerance and potential drug\u2013drug interactions. In this viewpoint, we outline different aspects of dose selection in the treatment of tuberculosis (TB) such as traditional pharmacokinetics\/pharmacodynamics, population pharmacokinetics models, the importance of real-world evidence and clinical trial design in the development of shorter treatment regimens and the new TB drug pipeline. Therapeutic drug monitoring for rifampicin, linezolid and amikacin may significantly improve their risk\u2013benefit profile promoting their responsible administration. Precision dosing of novel, repurposed or conventional TB drugs should ensure optimal efficacy, while minimising toxicity and the development of resistance.<\/jats:p>","DOI":"10.1183\/20734735.0177-2024","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T09:25:26Z","timestamp":1742289926000},"page":"240177","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The importance of getting the dose right in the treatment of tuberculosis"],"prefix":"10.1183","volume":"21","author":[{"given":"Andrii","family":"Dudnyk","sequence":"first","affiliation":[]},{"given":"Wandini","family":"Lutchmun","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3099","authenticated-orcid":false,"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4741","authenticated-orcid":false,"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[]},{"given":"Elin M.","family":"Svensson","sequence":"additional","affiliation":[]}],"member":"81","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2025031821300747000_21.1.240177.1","unstructured":"World Health Organization . Global tuberculosis report 2024. Geneva, World Health Organization, 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/379339\/9789240101531-eng.pdf"},{"key":"2025031821300747000_21.1.240177.2","doi-asserted-by":"publisher","DOI":"10.1097\/01.blo.0000175887.98112.fe"},{"key":"2025031821300747000_21.1.240177.3","unstructured":"US Food and Drug Administration . Step 3: Clinical Research. Date last updated: 4 January 2018. www.fda.gov\/patients\/drug-development-process\/step-3-clinical-research"},{"key":"2025031821300747000_21.1.240177.4","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1093\/jac\/dkz319","article-title":"How long will treatment guidelines for TB continue to overlook variability in drug exposure?","volume":"74","author":"Muliaditan","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025031821300747000_21.1.240177.5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40262-017-0577-6","article-title":"Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy","volume":"57","author":"Svensson","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2025031821300747000_21.1.240177.6","first-page":"355","article-title":"American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children","volume":"134","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"2025031821300747000_21.1.240177.7","unstructured":"World Health Organization . WHO operational handbook on tuberculosis. Module 4: treatment \u2013 drug-susceptible tuberculosis treatment. Geneva, World Health Organization, 2022. www.who.int\/publications\/i\/item\/9789240050761"},{"key":"2025031821300747000_21.1.240177.8","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment, 2022 update. Geneva, World Health Organization, 2022. www.who.int\/publications\/i\/item\/9789240063129"},{"key":"2025031821300747000_21.1.240177.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"2025031821300747000_21.1.240177.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00811-2"},{"key":"2025031821300747000_21.1.240177.11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5588\/ijtld.22.0188","article-title":"Clinical standards for the dosing and management of TB drugs","volume":"26","author":"Alffenaar","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025031821300747000_21.1.240177.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002773"},{"key":"2025031821300747000_21.1.240177.13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","article-title":"Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs","volume":"60","author":"Sturkenboom","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2025031821300747000_21.1.240177.14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/cid\/ciz1071","article-title":"Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials","volume":"71","author":"Svensson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025031821300747000_21.1.240177.15","first-page":"3081422","article-title":"Pharmacometrics: a new era of pharmacotherapy and drug development in low- and middle-income countries","volume":"2023","author":"Usman","year":"2023","journal-title":"Adv Pharmacol Pharm Sci"},{"key":"2025031821300747000_21.1.240177.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2025031821300747000_21.1.240177.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2025031821300747000_21.1.240177.18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang'wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025031821300747000_21.1.240177.19","doi-asserted-by":"crossref","unstructured":"World Health Organization . Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024. Geneva, World Health Organization, 2024. https:\/\/doi.org\/10.2471\/B09123","DOI":"10.2471\/B09123"},{"key":"2025031821300747000_21.1.240177.20","doi-asserted-by":"crossref","first-page":"e1002851","DOI":"10.1371\/journal.pmed.1002851","article-title":"Accelerating the transition of new tuberculosis drug combinations from phase II to phase III trials: new technologies and innovative designs","volume":"16","author":"Davies","year":"2019","journal-title":"PLoS Med"},{"key":"2025031821300747000_21.1.240177.21","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.crphar.2020.100007","article-title":"Tuberculosis and pharmacological interactions: a narrative review","volume":"2","author":"Riccardi","year":"2020","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2025031821300747000_21.1.240177.22","unstructured":"Office of AIDS Research, National Institutes of Health . Considerations for antiretroviral use in people with coinfections. Date last updated: 12 September 2024. Date last accessed: 14 October 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/tuberculosishiv-coinfection"},{"key":"2025031821300747000_21.1.240177.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00303-2024"},{"key":"2025031821300747000_21.1.240177.24","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1038\/s41467-024-50781-4","article-title":"Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen","volume":"15","author":"Strydom","year":"2024","journal-title":"Nat Commun"},{"key":"2025031821300747000_21.1.240177.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0224-2"},{"key":"2025031821300747000_21.1.240177.26","unstructured":"Center for Tuberculosis, University of California San Francisco . Therapeutics trials and pharmacokinetics. Date last accessed: 8 April 2024. https:\/\/tb.ucsf.edu\/therapeutics-trials-pharmacokinetics"},{"key":"2025031821300747000_21.1.240177.27","unstructured":"World Health Organization . Technical report on the pharmacokinetics and pharmacodynamics (PK\/PD) of medicines used in the treatment of drug-resistant tuberculosis. Geneva, World Health Organization, 2018. https:\/\/iris.who.int\/bitstream\/handle\/10665\/260440\/WHO-CDS-TB-2018.6-eng.pdf"},{"key":"2025031821300747000_21.1.240177.28","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkab075","article-title":"Saliva-based linezolid monitoring on a mobile UV spectrophotometer","volume":"76","author":"Kim","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025031821300747000_21.1.240177.29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5588\/ijtld.24.0022","article-title":"Reply to \u2018Therapeutic drug monitoring for isoniazid and rifampicin exposure\u2019","volume":"28","author":"Akkerman","year":"2024","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025031821300747000_21.1.240177.30","doi-asserted-by":"crossref","first-page":"37853","DOI":"10.1038\/srep37853","article-title":"Optimising antibiotic usage to treat bacterial infections","volume":"6","author":"Paterson","year":"2016","journal-title":"Sci Rep"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0177-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:30:31Z","timestamp":1742358631000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0177-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,18]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1183\/20734735.0177-2024"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0177-2024","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"type":"print","value":"1810-6838"},{"type":"electronic","value":"2073-4735"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}